Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,934 result(s) found for: Informed Consent. Displaying page 715 of 1,447.
    «« First « Previous 711  712  713  714  715  716  717  718  719  Next» Last»»
    EudraCT Number: 2014-001545-25 Sponsor Protocol Number: CHDR1409 Start Date*: 2014-07-02
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys...
    Medical condition: Healthy volunteers (balance disorders)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10049848 Balance disorder PT
    17.0 10029205 - Nervous system disorders 10004070 Balance difficulty LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003956-30 Sponsor Protocol Number: CHDR1429 Start Date*: 2014-10-13
    Sponsor Name:Centre for Human Drug Research
    Full Title: A single-centre randomized double-blind, double-dummy, placebo-controlled, four-way crossover study in healthy subjects to investigate the effect of ethanol 0.5 and 1.0 g/L and alprazolam 1 mg on a...
    Medical condition: A total of 24 healthy subjects, both male and female, will be enrolled into the study following satisfactory completion of a screening visit where eligibility for the study will be checked. Subje...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003336-72 Sponsor Protocol Number: 81413F Start Date*: 2013-10-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLGIA
    Full Title: A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)
    Medical condition: BASAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005666-36 Sponsor Protocol Number: IBCSG 22-00 Start Date*: 2009-12-07
    Sponsor Name:International Breast Cancer Study Group
    Full Title: Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non-...
    Medical condition: Histologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node pro...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002853-13 Sponsor Protocol Number: EWALL-BOLD Start Date*: 2018-03-01
    Sponsor Name:Goethe Universität Frankfurt
    Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli...
    Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005820-24 Sponsor Protocol Number: IIS-PICATO1264 Start Date*: 2016-09-09
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: A randomized study to evaluate the efficacy of ingenol mebutate on actinic keratoses and field cancerization compared to cryotherapy
    Medical condition: actinic keratoses and field cancerization
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001034-18 Sponsor Protocol Number: PETMR-Staging-PCa1 Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study to evaluate a novel approach for staging prostate cancer patients by using a fully integrated hybrid PET/MRI
    Medical condition: Patient diagnosed with prostatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005906-83 Sponsor Protocol Number: LYR-210-2021-004 Start Date*: 2022-08-05
    Sponsor Name:Lyra Therapeutics, Inc.
    Full Title: ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults
    Medical condition: Chronic Rhinosinusitis (CRS) in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) ES (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004972-32 Sponsor Protocol Number: CQVM149C2201 Start Date*: 2022-06-23
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004129-33 Sponsor Protocol Number: CRC2017EVO Start Date*: 2018-08-02
    Sponsor Name:Friedrich-Alexander-Universtiy Erlangen-Nürnberg, Medical Faculty
    Full Title: Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.
    Medical condition: atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001483-30 Sponsor Protocol Number: BBH-GMCSF-01 Start Date*: 2020-06-18
    Sponsor Name:Reponex Pharmaceuticals A/S
    Full Title: Effect of topical rhGM-CSF on the healing of venous leg ulcers: a randomized, placebo-controlled, double-blind, clinical phase II study
    Medical condition: Venous leg ulcers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10047260 Venous ulceration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004054-24 Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK Start Date*: 2019-03-18
    Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy
    Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006911-27 Sponsor Protocol Number: LYR-210-2021-005 Start Date*: 2022-07-28
    Sponsor Name:Lyra Therapeutics, Inc.
    Full Title: ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults
    Medical condition: Chronic Rhinosinusitis (CRS) in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000051-15 Sponsor Protocol Number: A4061008 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical Trials
    Medical condition: Patients who have been treated in previous AG-013736 oncology studies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003914-42 Sponsor Protocol Number: CEFTAROLINE_RRT Start Date*: 2013-11-06
    Sponsor Name:Medizinische Universität Wien, Univ.-Klinik für Innere Medizin I, Klinische Abteilung für Infetionen und Tropenmedizin
    Full Title: Multiple-dose Pharmacokinetics of Ceftaroline during continuous and intermittent renal replacement therapy in patients requiring renal replacement therapy
    Medical condition: Bacterial infection in patients recieving renal replacement therapy
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10060945 Bacterial infection PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2025-000142-26 Sponsor Protocol Number: 217091 Start Date*: 2025-04-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Multi-Centre, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subcutaneously Administered Belimumab Plus Standard Therapy in Chinese Paediatric Participants with Systemic Lupus Er...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-004656-14 Sponsor Protocol Number: BGB-A317-A1217-301 Start Date*: 2021-11-02
    Sponsor Name:BeiGene, Ltd.
    Full Title: Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizu...
    Medical condition: Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002121-30 Sponsor Protocol Number: 1704R2133 Start Date*: 2020-04-17
    Sponsor Name:Shionogi B.V.
    Full Title: An Open-label Study with a Nonrandomized Single-dose Phase in Subjects with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections followed by a Randomized, Multiple-dose, Active-control...
    Medical condition: Single dose: Pneumonia, cUTI, complicated intra-abdominal infections [cIAI], hospital acquired bacterial pneumonia [HABP]/ventilator-associated bacterial pneumonia [VABP], and sepsis or bloodstream...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    24.1 10021881 - Infections and infestations 10003997 Bacteraemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) GR (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006083-57 Sponsor Protocol Number: CA184-025 Start Date*: 2006-10-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol...
    Medical condition: Stage III, IV metastatic advanced melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Prematurely Ended) AT (Completed) HU (Completed) FI (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003131-11 Sponsor Protocol Number: 1280-0022 Start Date*: 2018-12-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: XeneraTM-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemest...
    Medical condition: HR+ / HER2- metastatic breast cancer and non-visceral disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) GR (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 711  712  713  714  715  716  717  718  719  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 20:49:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA